Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.

Kobayashi S, Ogura M, Hosoya T.

J Clin Pharm Ther. 2013 Jun;38(3):258-61. doi: 10.1111/jcpt.12057. Epub 2013 Mar 18.

PMID:
23506426
2.

Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.

Yu KH.

Recent Pat Inflamm Allergy Drug Discov. 2007 Feb;1(1):69-75. Review.

PMID:
19075968
3.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
4.
5.

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Stevenson M, Pandor A.

Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06. Review.

6.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

PMID:
19447778
7.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
8.

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

Bruce SP.

Ann Pharmacother. 2006 Dec;40(12):2187-94. Epub 2006 Nov 28. Review.

PMID:
17132810
9.

Febuxostat.

Hair PI, McCormack PL, Keating GM.

Drugs. 2008;68(13):1865-74. Review.

PMID:
18729537
10.

Febuxostat: a new agent for lowering serum urate.

Keenan RT, Pillinger MH.

Drugs Today (Barc). 2009 Apr;45(4):247-60. doi: 10.1358/dot.2009.45.4.1354217. Review.

PMID:
19499090
11.

Febuxostat (Uloric) for chronic treatment of gout.

[No authors listed]

Med Lett Drugs Ther. 2009 May 18;51(1312):37-8. Review.

PMID:
19448587
12.

Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.

Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q.

Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011. Epub 2013 Jan 16. Review.

PMID:
23332451
13.

Febuxostat for treatment of chronic gout.

Gray CL, Walters-Smith NE.

Am J Health Syst Pharm. 2011 Mar 1;68(5):389-98. doi: 10.2146/ajhp100394. Review.

PMID:
21330679
14.

Febuxostat for the chronic management of hyperuricemia in patients with gout.

Chinchilla SP, Urionaguena I, Perez-Ruiz F.

Expert Rev Clin Pharmacol. 2016;9(5):665-73. doi: 10.1586/17512433.2016.1162094. Epub 2016 Mar 25. Review.

PMID:
26942273
15.

Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.

Curiel RV, Guzman NJ.

Semin Arthritis Rheum. 2012 Oct;42(2):166-78. doi: 10.1016/j.semarthrit.2012.03.013. Epub 2012 May 3. Review.

PMID:
22560299
16.

Febuxostat: drug review and update.

Grewal HK, Martinez JR, Espinoza LR.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):747-58. doi: 10.1517/17425255.2014.904285. Epub 2014 Apr 1. Review.

PMID:
24684266
17.

Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.

Stamp L, Dalbeth N.

Semin Arthritis Rheum. 2017 Feb;46(4):457-464. doi: 10.1016/j.semarthrit.2016.07.015. Epub 2016 Jul 28. Review.

PMID:
27591828
18.

Update on gout and hyperuricemia.

Baker JF, Schumacher HR.

Int J Clin Pract. 2010 Feb;64(3):371-7. doi: 10.1111/j.1742-1241.2009.02188.x. Epub 2009 Nov 10. Review.

PMID:
19909378
19.

Emerging therapies in the long-term management of hyperuricaemia and gout.

Stamp LK, O'Donnell JL, Chapman PT.

Intern Med J. 2007 Apr;37(4):258-66. Review.

PMID:
17388867
20.

An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout.

Nuki G.

Curr Opin Rheumatol. 2014 Mar;26(2):152-61. doi: 10.1097/BOR.0000000000000034. Review.

PMID:
24492863

Supplemental Content

Support Center